Tongxiening granule in the treatment of diarrhea-predominant irritable bowel syndrome (stagnation of the liver-qi attacking the spleen): A prospective, randomized, placebo-controlled, double-blind clinical trial

Chinese Journal of Evidence-Based Medicine

Volumn 6, Issue 2, 2006, Pages 84-87

  Wang, Gang ^a   Li, Ting Qian ^a   Wang, Lei ^a   Xia, Qin ^a   Cheng, Yan ^a   Zhang, Rui Ming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Double blind; Irritable bowel syndrome; Randomized controlled trials; Tongxiening granule

Indexed keywords

CHINESE DRUG; PLACEBO; TONGXIENING; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CHINESE MEDICINE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG GRANULE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IRRITABLE COLON; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 33644785904     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut, 1999; 45(suppl 2): 43-47.
2. Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol, 1995; 142(1): 76-83.
3. Heaton KW, O'Donnell LJ, Braddon FE, et al. Symptoms of irritable bowel syndrome in a Brithish urban community: consulters and nonconsulters. Gastroenterology, 1992; 102(6): 1962-1927.
4. Heaton KW, Radvan J, Cripps H, et al. Defection frequency and timing, and stool form in the general population: a prospective study. Gut, 1992; 33(6): 818-824.
5. Chen LY, Ho kY, Phua kH. Normal bowel habits and prevalence of functional bowel disorders in Singaporean adults-findings from a community based study in Bishan. Community Medicine GI Study Group. Singapore Med J, 2000; 41(6): 255-258.
6. Chang L. Review article; epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther, 2004; 20 (Suppl 7): 31-33.
7. Pan GZ, Lu SC, Ke MY, et al. An epidemiologic study of irritable bowel syndrome in Beijing-As tratified randomized study by clustering sampling. Chinese Journal of Epidemiology, 2000; 21(1): 26-29.
8. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome[M/CD]. Cochrane Database Syst Rev, 2005; (2): CD003460.
9. Evans BW, Clark WK, Moore DJ, et al. Tegaserod for the treatment of irritable bowel syndrome[M/CD]. Cochrane Database Syst Rev, 2004; (1): CD003960.
10. Lackner JM, Mesmer C, Morley S, et al. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol, 2004; 72(6); 1100-1113.
11. Lesbros-Pantoflichova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2004; 20(11-12): 1253-1269.
12. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol, 2003; 56(4): 362-369.
13. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med, 2003; 163(3): 265-274.
14. Tan S, Tillisch K, Bolus SR, et al. Traditional Chinese medicine based subgrouping of irritable bowel syndrome patients. Am J Chin Med, 2005; 33(3): 365-379.
15. Sung JJ, Leung WK, Ching JY, et al. Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2004; 20(10): 1205-1210.
16. Bensooussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA, 1998; 280(18): 1585-1589.
17. Yuan R, Lin Y. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol Ther, 2000; 86(2): 191-198.
18. Chinese Society of Gastroenerology. The uniform on irritable bowel syndrome. Chinese Journal of Internal Medicine, 2003; 42(9): 669-670.
19. Cheng ZS, Zhang WD, Wei BH. Schedule for Diagnosis and Treatment of Irritable Bowel Syndrome with Integrative Chinese and Western Medicine (Draft). Chinese Journal of Integrated Traditional and Western Medicine, 2005; 25(3): 282-284.
20. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, 2000; 284: 3043-3045.
21. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastroenterol, 1998; 93(7): 1131-1135.
22. Grigoleit HG, Grigoleit P. Peppermint oil in irritable bowel syndrome. Phytomedicine, 2005; 12(8): 601-606.
23. Brinkhaus B, Hentschel C, Von Keudell C, et al. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol, 2005; 40(8): 936-943.
24. Bundy R, Walker AF, Middleton RW, et al. Artichoke leaf extract reduces reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis. J Altern Complenent Med, 2004; 10 (4): 667-669.
25. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther, 2004; 19(3): 271-279.
26. Baer N. Debate about placebos points to issue surrounded by many shades of grey. CMAJ, 1996; 155(10): 1475-1476.
27. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil, 2005; 17(3): 332-340.
28. Moher D, Schulz KF, Altman D, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA, 2001; 285(15): 1987-1991.